Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Mariangela Tamburello
Observed names:
M Tamburello,
M. Tamburello,
Mariangela TAMBURELLO,
Tamburello, Mariangela
Institutions:
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia,
University of Brescia
Observed institutions:
University of Würzburg,
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia,
Universitätsklinikum Würzburg,
University of Brescia
ORCID:
0000-0001-7827-0025
Observed ORCID:
0000-0001-7827-0025
OpenAlex ID:
A5006486947
An update on adrenocortical cell lines of human origin
2022
·
Sandra Sigala
, Elisa Rossini
, et al.
·
Endocrine
·
29
PDF
Advances in adrenocortical carcinoma pharmacotherapy: what is the current state of the art?
2022
·
Valentina Cremaschi
, Andrea Abate
, et al.
·
Expert Opinion on Pharmacotherapy
·
25
FSCN1 as a new druggable target in adrenocortical carcinoma
2023
·
Carmen Ruggiero
, Mariangela Tamburello
, et al.
·
International Journal of Cancer
·
23
PDF
Erythropoiesis in Cushing syndrome: sex-related and subtype-specific differences. Results from a monocentric study
2023
·
M. Detomas
, T. Deutschbein
, et al.
·
Journal of Endocrinological Investigation
·
21
PDF
Cytotoxic Effect of Progesterone, Tamoxifen and Their Combination in Experimental Cell Models of Human Adrenocortical Cancer
2021
·
Elisa Rossini
, Mariangela Tamburello
, et al.
·
Frontiers in Endocrinology
·
21
PDF
FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinoma
2022
·
Mariangela Tamburello
, Barbara Altieri
, et al.
·
Endocrine
·
20
PDF
Estrogen-Like Effect of Mitotane Explained by Its Agonist Activity on Estrogen Receptor-α
2021
·
Elisa Rossini
, Edoardo Giacopuzzi
, et al.
·
Biomedicines
·
17
PDF
Preclinical Evidence of Progesterone as a New Pharmacological Strategy in Human Adrenocortical Carcinoma Cell Lines
2023
·
Mariangela Tamburello
, Andrea Abate
, et al.
·
International Journal of Molecular Sciences
·
16
PDF
Trabectedin impairs invasiveness and metastasis in adrenocortical carcinoma preclinical models
2022
·
Andrea Abate
, Mariangela Tamburello
, et al.
·
Endocrine Related Cancer
·
15
Ribociclib Cytotoxicity Alone or Combined With Progesterone and/or Mitotane in in Vitro Adrenocortical Carcinoma Cells
2021
·
Andrea Abate
, Elisa Rossini
, et al.
·
Endocrinology
·
14
PDF
Dlk1 is a novel adrenocortical stem/progenitor cell marker that predicts malignancy in adrenocortical carcinoma
2025
·
Katia Mariniello
, James F. H. Pittaway
, et al.
·
癌症:英文版
·
13
The CDK Inhibitor Dinaciclib Improves Cisplatin Response in Nonseminomatous Testicular Cancer: A Preclinical Study
2024
·
Elisa Rossini
, Mariangela Tamburello
, et al.
·
Cells
·
11
PDF
Emerging role of IGF1R and IR expression and localisation in adrenocortical carcinomas
2025
·
Rosa Catalano
, Emma Nozza
, et al.
·
Cell Communication and Signaling
·
6
Cancer cell xenografts in zebrafish embryos as an experimental tool in drug screening for adrenocortical carcinoma
2025
·
Mariangela TAMBURELLO
, Andrea ABATE
, et al.
·
Minerva Endocrinology
·
6
A Database Tool Integrating Genomic and Pharmacologic Data from Adrenocortical Carcinoma Cell Lines, PDX, and Patient Samples
2024
·
Yasuhiro Arakawa
, Fathi Elloumi
, et al.
·
Cancer Research Communications
·
6
Pharmacological WEE1 inhibition as a strategy to overcome cisplatin resistance in non-seminoma testicular cancer: insights from preclinical models
2026
·
Mariangela Tamburello
, Caterina Boldini
, et al.
·
Scientific Reports
·
5
PDF
Feasibility and Activity of Megestrol Acetate in Addition to Etoposide, Doxorubicin, Cisplatin, and Mitotane as First-Line Therapy in Patients with Metastatic/Unresectable Adrenocortical Carcinoma with Low Performance Status
2023
·
Antonella Turla
, Marta Laganà
, et al.
·
Cancers
·
5
PDF
Chemo–immunotherapy with cisplatin and nivolumab as second-line approach in metastatic adrenocortical carcinoma
2026
·
Marta Laganà
, Sara Rodella
, et al.
·
European Journal of Endocrinology
·
4
PPARG dysregulation as a potential molecular target in adrenal Cushing's syndrome
2023
·
Sharmilee Vetrivel
, Mariangela Tamburello
, et al.
·
Frontiers in Endocrinology
·
3
PDF
Outcome of brain metastases from adrenocortical carcinoma: a pooled analysis
2023
·
A. Turla
, M. Laganà
, et al.
·
Journal of Endocrinological Investigation
·
3
PDF
FGF/FGFR inhibitors downmodulates c-Myc oncoprotein and hampers the growth of adrenocortical carcinoma
2025
·
Sara Taranto
, Jessica Faletti
, et al.
·
Biomedicine & Pharmacotherapy
·
2
Prognostic role of pretreatment [18F]FDG PET/CT in patients affected by adrenocortical carcinoma and treated with chemotherapy
2026
·
Francesco Dondi
, Davide Lorenzo Bettini
, et al.
·
European Journal of Nuclear Medicine and Molecular Imaging
·
1
PDF
Preclinical evaluation of progesterone combined with EDP-M scheme in 2D and 3D models of adrenocortical carcinoma
2026
·
Mariangela Tamburello
, Andrea Abate
, et al.
·
Biomedicine & Pharmacotherapy
·
1
Preclinic and Translational Research in Adrenal Malignancies
2024
·
Elena Rapizzi
, Andrea Abate
, et al.
·
Updates in surgery/Updates in surgery series
·
1
40TiP Activity of the addition of progesterone to standard EDP-M scheme in patients with advanced adrenocortical carcinoma: A randomized, placebo-controlled phase II trial (PESETA)
2023
·
V. Cremaschi
, D. Cosentini
, et al.
·
ESMO Open
·
1
PDF
Show more works
View as search
Works count:
77
Citation count:
269
H-index:
11
I10-index:
12
Year
Topic
Type